NCT07409272 2026-04-16
A Study to Evaluate the Effectiveness and Safety of Setidegrasib, Given With Either mFOLFIRINOX or NALIRIFOX Chemotherapies, in People With Pancreatic Cancer
Astellas Pharma Inc
Phase 3 Recruiting
Clinical Trials
25 trialsNCT06593431 2026-04-15
Extending Outcomes for Pancreas Cancer Patients With Nominal Oligometastatic Disease (EXPAND): A Randomized Phase III Trial
M.D. Anderson Cancer Center
Phase 3 Recruiting
NCT07522073 2026-04-13
DAWN-303
Incyte Corporation
Phase 3 Recruiting
NCT06958328 2026-04-08
LAP100
NRG Oncology
Phase 3 Recruiting
NCT07252232 2026-04-06
RASolute 304
Revolution Medicines, Inc.
Phase 3 Recruiting
NCT07491445 2026-04-06
RASolute 303
Revolution Medicines, Inc.
Phase 3 Recruiting
NCT06807437 2026-03-31
Lanreotide Versus Placebo Before Surgery to Prevent a Surgical Complication Called a Pancreatic Fistula
SWOG Cancer Research Network
Phase 3 Recruiting
NCT06998940 2026-03-27
Studying Chemotherapy With or Without Panitumumab for Unresectable, Locally Advanced, or Metastatic Pancreatic Cancer Without KRAS Mutations
SWOG Cancer Research Network
Phase 3 Recruiting
NCT06953999 2026-03-04
A Phase III Study of Ivonescimab + Chemo With/Without AK117 in Metastatic Pancreatic Cancer
Akeso
Phase 3 Recruiting
NCT05720338 2026-02-19
Is Intraperitoneal Drainage Necessary Following Distal Pancreatectomy?
Case Comprehensive Cancer Center
Phase 3 Recruiting
NCT06861088 2026-02-02
CATIQ P3
Quercis Pharma AG
Phase 3 Recruiting
NCT02000089 2025-10-09
CAPS5
Johns Hopkins University
Phase 3 Recruiting
NCT07079228 2025-09-23
A Study to Compare QLS31905 and Chemotherapy With Placebo and Chemotherapy in Participants With Pancreatic Cancer
Qilu Pharmaceutical Co., Ltd.
Phase 3 Recruiting
NCT07155525 2025-09-18
NBCA-MS
Minia University
Phase 3 Recruiting
NCT07081360 2025-08-29
Neoadjuvant vs Upfront Surgery for Resectable Pancreatic Cancer and Periampullary Cancer
Minia University
Phase 3 Recruiting
NCT07066098 2025-08-15
A Multicenter Study of IBI343 Monotherapy Versus Placebo in Subjects With Previously Treated, Claudin (CLDN) 18.2-positive, Pancreatic Cancer(G-HOPE-002)
Innovent Biologics (Suzhou) Co. Ltd.
Phase 3 Recruiting
NCT06897644 2025-05-25
PANThEON
Gruppo Oncologico del Nord-Ovest
Phase 3 Recruiting
NCT06332274 2025-05-13
UMBRELLA
Gustave Roussy, Cancer Campus, Grand Paris
Phase 3 Recruiting
NCT06427447 2025-02-04
ADJUPANC
Changhai Hospital
Phase 3 Recruiting
NCT06714604 2024-12-03
ADVANTAGE
Sahlgrenska University Hospital
Phase 3 Recruiting
NCT05744219 2024-10-21
IRIS
Uppsala University Hospital
Phase 3 Recruiting
NCT04927780 2024-08-28
PREOPANC-3
Erasmus Medical Center
Phase 3 Recruiting
NCT06391892 2024-04-30
LIQUIPANC
Elisabethinen Hospital
Phase 3 Recruiting
NCT06017284 2023-11-24
PTCA199-5
Fudan University
Phase 3 Recruiting
NCT04969731 2021-11-22
Safety and Efficacy of Immuncell-LC With Gemcitabine in Resectable Pancreatic Cancer
GC Cell Corporation
Phase 3 Recruiting